WO2026110076 - THE COMBINATION OF A CD137 AGONIST AND ALTERNATING ELECTRIC FIELD THERAPY FOR USE IN THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2026/110076
Publication Date
28.05.2026
International Application No.
PCT/IB2025/061905
International Filing Date
20.11.2025
Title **
[English]
THE COMBINATION OF A CD137 AGONIST AND ALTERNATING ELECTRIC FIELD THERAPY FOR USE IN THE TREATMENT OF CANCER
[French]
COMBINAISON D'UN AGONISTE DE CD137 ET D'UNE THÉRAPIE PAR CHAMP ÉLECTRIQUE ALTERNATIF DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DU CANCER
Applicants **
NOVOCURE GMBH
PICCIRILLO, Sara
Inventors
ORBACH, Ayelet
Priority Data
63/723,073
20.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2268 | |
| EPO | Filing, Examination, Granting | 9055 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,289
Contact Us
Abstract[English]
Disclosed are methods of treating a subject in need thereof comprising applying an alternating electric field to a target site of the subject in need thereof; and administering one or more CD137 agonists to the subject in need thereof. Disclosed are methods of promoting an effector T (Teff) cell immune response, decreasing immune suppression, decreasing mitochondrial respiration of regulatory T (Treg) cells, and reducing expansion of Treg cells in a subject in need thereof comprising applying an alternating electric field to a target site of the subject in need thereof; and administering one or more CD137 agonists to the subject in need thereof.[French]
L'invention concerne des méthodes de traitement d'un sujet en ayant besoin, comprenant l'application d'un champ électrique alternatif sur un site cible du sujet en ayant besoin; et l'administration d'un ou plusieurs agonistes de CD137 au sujet en ayant besoin. L'invention concerne des méthodes de promotion d'une réponse immunitaire de lymphocytes T effecteurs (Teff), de diminution de la suppression immunitaire, de diminution de la respiration mitochondriale des lymphocytes T régulateurs (Treg), et de réduction de l'expansion des cellules Treg chez un sujet en ayant besoin, comprenant l'application d'un champ électrique alternatif sur un site cible du sujet en ayant besoin; et l'administration d'un ou de plusieurs agonistes de CD137 au sujet en ayant besoin. #4906-0520-1785 v4